Similarly, we found that only three DEGs (SCRG1, CDKN1A, SLC2A3) had a significant P-value in the RNA-seq data validation step, and only the SCRG1 gene showed a consistent expression trend, which was increased in the OA synovitis samples, so SCRG1 may be a reliable biomarker and therapeutic target for OA diseases. This evidence concerns the gene SLC2A3 and synovitis.